New Risk • May 17
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$851k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$16m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$851k). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.38m market cap). Announcement • May 16
Glucotrack, Inc. Receives Nasdaq Notice for Failure to Comply with the Minimum Stockholders’ Equity Requirement As previously disclosed, on May 11, 2026, Glucotrack, Inc. (the Company) received a Staff Determination letter (the Staff Determination) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules which requires listed securities to maintain a minimum bid price of $1.00 per share (the Bid Price Rule), and that the Nasdaq staff (the Nasdaq Staff) had determined to delist the Company's securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the Panel) by May 18, 2026, to appeal Nasdaq Staff's determination. A timely hearing request will stay any further delisting actions through the hearing process. At the hearing, the Company expects to present its plan to regain compliance with the Bid Price Rule. On May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March 31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders' equity requirement for continued listing set forth under Listing Rule 5550(b)(1) (the Minimum Stockholders' Equity Requirement), and the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. Accordingly, the failure to comply with the Minimum Stockholders' Equity Requirement has become an additional basis for delisting. The Nasdaq Staff further notified the Company that failure to meet the Minimum Stockholders' Equity Requirement will be considered in its decision regarding the Company's continued listing on The Nasdaq Capital Market. The Company intends to present its views with respect to this additional deficiency to the Panel at its hearing. There can be no assurance that the Company will be successful in its appeal, that the Panel will grant the Company's request for continued listing, or that the Company will be able to regain or maintain compliance with any applicable Nasdaq listing requirements. Announcement • Apr 23
Glucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring Technology Glucotrack, Inc. had announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company’s fully implantable continuous blood glucose monitoring (CBGM) system. The findings represent the first year-long measurement of glucose oxidase enzyme decay reported in the literature and support the feasibility of long-life implantable continuous glucose monitors. The publication, titled “Year-Long Measurement of Glucose Oxidase Deactivation in Electrochemical Glucose Sensors,” (Ernst, S. et al.), examined the long-term in-vitro performance and stability of an electrochemical glucose sensor based on glucose oxidase, the enzyme class used in Glucotrack’s CBGM, over a one-year period. The objective of the study was to assess sensor performance during the final year of its intended functional life. Accordingly, sensors used in the study were constructed to reflect approximately two year old devices. The findings represent the first year-long measurement of glucose oxidase enzyme decay, providing higher-confidence in the design of long-life implantable glucose sensor. Glucotrack partnered with TTP, a United Kingdom-based scientific and engineering organization with experience supporting life sciences and medical device innovation, for this study and publication. The article was published on April 7, 2026 in the highly regarded technical journal, the IEEE Sensors Journal, part of the Institute of Electrical and Electronics Engineers, a global organization of over 486,000 STEM professionals worldwide. This publication is one part of Glucotrack’s ongoing effort to build a transparent, peer-reviewed technical foundation for the development of its CBGM technology. Glucotrack previously reported first-in-human clinical results demonstrating a highly-accurate MARD of 7.7% and a 99% data capture rate, with no procedure- or device-related serious adverse events. Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. 
